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We have found that A Disintegrin And Metalloproteinase-9 (ADAM9) localises to cell-cell junctions with
VE-Cadherin in conﬂuent endothelial monolayers. Co-cultures of cells separately transfected with
ADAM9-EGFP or ADAM9-HA showed expression is required in two adjacent cells for localisation to cell-
cell junctions suggesting the ADAM9 ectodomain may self-associate. A direct interaction between
ADAM9 ectodomains was conﬁrmed using recombinant proteins and an ELISA based method. As the
ADAM9 ectodomain can also exist as a soluble form physiologically, we examined if this could inhibit
endothelial functions dependent on cell-cell junctions. The soluble ADAM9 ectodomain could not in-
crease endothelial monolayer permeability or inhibit monocyte-endothelial adhesion, but could inhibit
monocyte-endothelial transmigration. These novel ﬁndings point to ADAM9 playing an important role in
endothelial cell biology that is distinct from the other ADAMs.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The A Disintegrin And Metalloproteinase (ADAM) family of
proteins consists of 33 members that regulate an array of cellular
processes including cell-cell fusion, cell adhesion andmigration [1].
The proteolytically active members regulate these and other
cellular processes through ectodomain shedding of cell surface
cytokines, growth factors and receptors [1,2]. ADAMs have also
been shown to be integral to the regulation of cell-cell contact
dependent signalling, adhesion and migration via a variety of
mechanisms. This may be via proteolysis of cell-cell junction pro-
teins including N-cadherin, E-Cadherin, VE-Cadherin and Ephrins
[3,4] or via their association with integrins [5]. These interactions
are also important regulators of vascular endothelial cell function.
ADAMs have been shown to localise to cell-cell junctions, including
in endothelial cells [6e8]. ADAM10, 15, 17, and 28 have been shown
to regulate leukocyte transmigration across endothelial monolayersoteinase; EGFP, Enhanced Green Flu
5; ZO-1, zona occludens 1; Fc, F
nd Metabolism, The Medical Scho
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l Research Communications ([9,10], a process that is dependent on proteolysis, regulation of
phosphorylation of adherens junction proteins or interaction with
integrins. In some instances, ADAMs have been found to be secreted
as soluble forms, including ADAM9 and ADAM15 that can also in-
ﬂuence cell adhesion and migration [11e13]. We have previously
demonstrated that ADAM9 is able to shed angiotensin-converting
enzyme from endothelial cells stimulated with lipopolysaccharide
via a TNF-TNFR dependent mechanism [14]. However, the local-
isation of ADAM9 in endothelial cells is not characterised and it is
not known if it can regulate other aspects of endothelial biology e.g.
endothelial monolayer permeability, leukocyte-endothelial adhe-
sion or transmigration. In this article we investigated the local-
isation of ADAM9 in human umbilical vein endothelial cells
(HUVEC) to further understand its role in the regulation of endo-
thelial cell biology, leading to the identiﬁcation of a new function
for ADAM9 in endothelial monolayers.orescent Protein; HA, hemagglutinin; ELISA, Enzyme Linked Immunosorbent Assay;
c region of IgG.
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2.1. Cell culture
Pooled donor HUVECwere purchased cryo-preserved at passage
2 from TCS Cellworks and cultured in the supplied large vessel
endothelial culture medium up to a maximum of 12 population
doublings (approx. passage 4 to 5). 293T cells were obtained from
the Cancer Research UK collection and cultured in DMEM, 10% FCS
v/v, 500 mg ml1 L-glutamine and 100 units ml1 penicillin and
100 mg ml1 streptomycin. THP-1 were purchased from ECACC and
cultured in RPMI, 10% foetal calf serum (FCS) v/v and 100 units ml1
penicillin and 100 mg ml1 streptomycin. All cells were cultured at
37 C, 5% CO2, 100% humidity.
2.2. Immunoﬂuorescence staining of cell monolayers
HUVEC were cultured on glass coverslips at the times indicated
and ﬁxed with methanol at 20 C for 5 min prior to labelling in
phosphate buffered saline (PBS) with 10 mg ml1 of antibodies to
ADAM9 (Triple Point Biologics, RP3-ADAM9, USA) and either VE-
Cadherin (clone 75/Cadherin 5), ZO-1 (Clone 1) or g-Catenin
(Clone 15) purchased from BD Transduction Laboratories. Cells
were incubated with the primary antibody for 1 h before washing 3
times with PBS and then incubated with either anti-rabbit
Alexa488 or anti-mouse Alexa546 conjugated secondary anti-
bodies (1:1000, Invitrogen, UK) for 1 h, washed and mounted in
Mowiol. Imageswere obtained using a Zeiss LSM 510 confocal laser-
scanning microscope.
2.3. Cloning of ADAM9 chimeras and mutants
Mouse ADAM9 cDNA, ADAM9-Fc ectodomain (ECTO-Fc) in
pEE12were obtained as described previously [14]. The ECTO-Fcwas
cloned from pEE12 into pCDNA3.1 zeoþ using PCR. The soluble
ADAM9 ectomain (ECTO, residues 1 to 698), was cloned from pEE12
using PCR into the vector pSecTag2B allowing the addition of amyc-
[His]6 tag, producing ECTO-His. Alternatively, mouse ADAM9 ECTO-
His was purchased from R&D Systems. To generate ADAM9-EGFP
and ADAM9-HA, the complete ADAM9 cDNA was cloned from
pEE12 by PCR removing the stop codon and then cloned in frame
into pEGFP-N2 and pCDNA3.1 zeo þ respectively, thus generating
C-terminal tagged proteins. All PCR steps were veriﬁed by
sequencing.
2.4. Transient transfection of 239T cells with cDNAs expressing
ADAM9 chimeras
293T cells were chosen as we had previously found they express
very low levels of ADAM9 [14]. 293T cells were seeded at 3  105 in
six well tissue culture plates at the same time as the cDNA-Fugene6
(Roche GmbH) transfection mixture. The cells were separately
transfected with either ADAM9-HA or ADAM9-GFP cDNAs. 24 h
after transfection, the cells were washed 3 times with fresh me-
dium and then cultured for a further 24 h. The separately trans-
fected cells were then trypsinised and re-seeded together at a 1:1
ratio on 10 mm cover glasses placed in 12 well tissue culture plates
at 5  104 cells per well, resulting in the formation of a conﬂuent
monolayer. After 24 h, the cells were ﬁxed in 4% w/v para-
formaldehyde in PBS for 10 min, washed with PBS before incu-
bating in 100 mM glycine, 0.01% Triton X-100 (Thermoﬁsher, UK)
for 5 min. Cells were then incubated with a rabbit anti-HA poly-
clonal antibody (5 mg ml1, F-7, Santa Cruz) for 1 h, washed 3 x in
PBS before incubation with anti-mouse Texas red secondary anti-
body (1:500, Jackson Immunochemicals) for 1 h in PBS and aPlease cite this article in press as: W.R. English, et al., ADAM9 is present at
transmigration, Biochemical and Biophysical Research Communications (further 3 washes in PBS before mounting in Mowiol.
2.5. Puriﬁcation of soluble ADAM9 and mutants
The various soluble forms of ADAM9 were transiently trans-
fected into 293T cells by calcium phosphate precipitation. ECTO-Fc
was puriﬁed from cell culture medium by protein A afﬁnity chro-
matography at 4 C. Cell culture medium was sterile ﬁltered,
adjusted to 1.65 M NaCl, 0.9 M Glycine, pH 8.8 and loaded onto a
protein A column pre-equilibrated with 1.65 M NaCl, 0.9 M glycine
pH 8.8 and washed with the same buffer. ECTO-Fc was eluted with
0.1 M glycine, 0.5 M NaCl pH 2.5 and immediately neutralised with
Tris-HCl before dialysis against 50 mM Tris-HCl, 50 mM NaCl, pH
7.4. Myc-[His]6-tagged ADAM9 ectodomain (ECTO-His) was puri-
ﬁed by NiNTA afﬁnity chromatography. Medium was loaded over-
night at 4 C on a NiNTA-agarose column pre-equilibrated with
medium. The column was washed with 50 mM Tris-HCl, 500 mM
NaCl, 10 mM Imidazole, pH 8.0 and eluted with 50 mM Tris-HCl,
500 mM NaCl, 200 mM Imidazole, pH 8.0. Protein concentration
was estimated by BCA assay (Thermoﬁsher) and protein purity by
reducing SDS-PAGE followed by coomassie blue staining. Alterna-
tively protein was detected using western blotting detected using
enhanced chemiluminescence (ECL). The anti-Fc antibodywas from
Jackson Immunochemicals (1:1000) and the anti-myc antibodywas
from Cell Signalling Technology (1:1000, 9B11). Protein was then
stored in aliquots at 80 C. The mouse ADAM9 ectodomain with a
C-terminal [His]6 tag was also purchased from R&D systems.
2.6. ADAM9-ADAM9 ELISA
ADAM9 ectodomains were coated at 2 mg ml1 in 0.1 M Na2CO3
pH 9.8 overnight at 4 C onto NUNC-immuno maxisorb 96-well
plates. Plates were washed 3 x in PBS-Tween 20 (0.05%). Unspe-
ciﬁc binding was blocked by 1 h incubation with 200 ml PBS, 1%
Tween-20 v/v, 1% BSA w/v, 1% w/v fat free milk powder. This buffer
is also used for all incubations. ADAM9with a different tagwas then
incubated for 1 h at RT before washing 3 times with PBS-Tween 20.
Bound ADAM9 was detected by incubation for 1 h at RT with the
appropriate antibody at 5 mg ml1 and washed 3 times. Finally
detection was achieved with incubation for 1 h at RT with the
appropriate HRP-conjugated secondary antibody. The plate was
then washed 6 times with PBS-Tween 20. The plate was developed
by incubation with 100 ml TMB ONE ready-to-use substrate (KEM
EN TEC) and the reaction stopped by addition of 100 ml 0.2 M sul-
phuric acid. Absorbance was measured at 405 nm with a TECAN
Spectraﬂuor Plus microtitre plate reader.
2.7. Endothelial permeability and monocyte-endothelial
transmigration assay
100 ml 5 mg ml1 Fibronectin (Sigma Aldrich) in PBS was used to
coat 6 mm diameter transwells with a 3 mm pore size (Corning
Costar) for 1 h. 1  105 HUVEC were then seeded in large vessel
endothelial cell medium (LVECM) and cultured for 4 days to allow a
conﬂuent monolayer to form. For permeability assays, HUVEC were
incubated with ECTO-His at 3 mM for 2 h or with 300 mM H2O2 for
30 min [15]. 45 kDa FITC-dextran was added to the upper well at
0.8 mg ml1 for 30 min [16]. Fluorescence of the medium in the
lower well was measured in 96 well plates using a TECAN Spec-
traﬂuor Plus microtitre plate reader with excitation/emission
wavelengths of 435/495 nm. For transmigration assays, THP-1 cells
were resuspended in serum free medium in the presence of 2 mM
CMFDK green tracker dye (Invitrogen) for 30 min at 37 C before
centrifuging at 300 x g and resuspension in LVECM at 2  106 cell
ml1. 2  105 THP-1 cells were added to the transwell insert inendothelial cell - cell junctions and regulates monocytee endothelial
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Fig. 1. ADAM9 localises to cell-cell junctions in HUVEC. Confocal images of conﬂuent
HUVEC stained for ADAM9 (green) and either VE-Cadherin, ZO-1 or g-Catenin (red).
Merged image shows overlap in staining in yellow. Scale bars are 20 mm. (For inter-
pretation of the references to colour in this ﬁgure legend, the reader is referred to the
web version of this article.)
W.R. English et al. / Biochemical and Biophysical Research Communications xxx (2017) 1e6 3100 ml and migrationwas allowed to proceed for 4 h at 37 C. ECTO-
Fc or Fc alone were pre-incubated with the HUVEC monolayer and
THP-1 cells for 30min at 3 mMprior to addition of the THP-1 cells to
the monolayer. After 4 h the transwell insert was removed and the
medium from the lower chamber centrifuged at 300 x g. The me-
dium was removed and the pellet lysed in 100 ml cell lysis buffer.
This was combined with a 100 ml lysis buffer wash from the bottom
of the insert and lower chamber. Fluorescence of cell lysates was
measured on a TECAN Spectraﬂuor plus ﬂuorescence plate reader
in 96 well microtitre plates with excitation/emission wavelengths
of 435/495 nm.
2.8. Monocyte e endothelial adhesion assay
The monocyte adhesion assay was adapted from methodology
described by McGinn et al. [10]. Brieﬂy, HUVEC were grown to
conﬂuence in 96 well tissue culture plates. THP-1 cells were
labelled with CMFDK green tracker dye as described above. HUVEC
were pre-incubated with 3 mM ECTO-Fc for 30 min before addition
of 1  105 THP-1 cells, ensuring the ﬁnal concentration of ADAM9
remained 3 mM by adding it to the THP-1 cells. THP-1 were incu-
bated on the HUVEC monolayers for 30 min before removal of
medium containing non-adherent cells and ﬁxing with 4% w/v
paraformaldehyde for 20 min. The wells were washed with PBS
before ﬂuorescence was measured on a TECAN Spectraﬂor Plus
with excitation/emission wavelengths of 435/495 nm.
2.9. Statistical analysis of data
Grouped data was analysed using one-way ANOVAwith a Tukey
multiple comparisons post-test. Pair-wise comparisons were made
using an unpaired t-test with Welch's correction. Analysis was
performed using GraphPad Prism version 7.0c for Mac OSX,
GraphPad Software, La Jolla California USA, www.graphpad.com. *,
** and *** are used in the ﬁgures to indicate P < 0.05, 0.001 and
0.0001 respectively.
3. Results
3.1. ADAM9 localises to cell-cell junctions and co-localises with cell
- cell junction proteins in endothelial cells
ADAM9 was detected in conﬂuent HUVEC monolayers by
immunoﬂuorescence staining at cell-cell junctions, as well as
within vesicles throughout the cytosol. Co-staining with cell junc-
tion proteins VE-cadherin, g-catenin and ZO-1 conﬁrmed that
ADAM9 localises to cell-cell junctions (Fig. 1). Similar to ADAM15
[6], ADAM9 staining at cell junctions appeared concomitantly over
time with VE-Cadherin when HUVEC were seeded onto glass at
conﬂuency, and was absent when cell-cell contact was lost after
introducing a scratch wound in conﬂuent monolayers (Fig. 2A).
3.2. ADAM9 must be expressed by adjacent cells to localise to cell -
cell junctions
We next investigated if ADAM9 localisation at cell-cell junctions
was dependent on ADAM9 being expressed by two adjacent cells.
ADAM9 chimeric cDNAs were constructed with either EGFP or HA
tags at the C-terminus. 293T cells were transiently transfected
separately with either ADAM9-EGFP or ADAM9-HA before trypsi-
nisation and co-culturing together. ADAM9 was only seen at cell-
cell junctions when cells were expressing tagged ADAM9, and
only when both adjacent cells were expressing tagged ADAM9 as
seen by co-localisation of GFP and HA tagged ADAM9 to cell-cell
junctions (Fig. 2B).Please cite this article in press as: W.R. English, et al., ADAM9 is present at
transmigration, Biochemical and Biophysical Research Communications (3.3. ADAM9 can self-associate through ectodomain interactions
Our ﬁndings raised the possibility that ADAM9 may have the
ability to self-associate through ectodomain interactions. To
address this, recombinant ADAM9 ectodomains (ECTO) were
expressed in 293T cells with myc-[His]6 (His) or IgG Fc (Fc) C-ter-
minal fusions and puriﬁed from the cell conditioned medium
(Fig. 3A). By coating 96 well microtitre plates with either ECTO-His
or ECTO-Fc we found that ECTO-Fc or ECTO-His proteins, respec-
tively, showed association with the ADAM9 ectodomain coated on
the plate surface (Fig. 3B).
3.4. The soluble ADAM9 ectodomain inhibits endothelial -
monocyte transmigration
As the ADAM9 ectodomain has the ability to self-associate, we
hypothesised that the soluble ADAM9 ectodomain could compete
with ADAM9-ADAM9 interactions between endothelial cells, thus
impairing endothelial monolayer function and possibly increase
permeability, as reported for the addition of soluble VE-Cadherin to
endothelial monolayers [17]. HUVEC were seeded onto ﬁbronectin-
coated transwells and allowed to form a conﬂuent monolayer.
Contrary to our expectations, addition of the ADAM9 ectodomain to
endothelial monolayers had no signiﬁcant effect on permeability
(Fig. 4A). As cell-cell junctions in endothelial cells can also control
leukoycte-endothelial transmigration [18] and the ADAM28 ecto-
domain can regulate leukocyte-endothelial adhesion or trans-
migration [10], we speculated the ADAM9 ectodomain might also
regulate these processes. THP-1 adhesion to endothelial mono-
layers was not inhibited by ECTO-Fc signiﬁcantly, although a
decrease in adhesionwas detected (Fig. 4B). In contrast, addition of
the soluble ECTO-Fc ectodomain signiﬁcantly inhibited trans-
migration of THP-1 cells across conﬂuent HUVEC on ﬁbronectin-
coated transwells (Fig. 4C).
4. Discussion
ADAM9 is expressed in endothelial cells and has been shown to
play a role in neovascularisation both in retinal development and inendothelial cell - cell junctions and regulates monocytee endothelial
2017), https://doi.org/10.1016/j.bbrc.2017.09.089
Fig. 2. ADAM9 moves from a cytosolic localisation to cell-cell junctions in HUVEC during
formation of a conﬂuent monolayer and must be expressed by two adjacent cells. A.
HUVEC were seeded at high density to ensure formation of a conﬂuent monolayer after
cell spreading was complete and ﬁxed at 0.5e6 h intervals before staining for VE-
Cadherin (red) and ADAM9 (green) and imaged using confocal microscopy. In addi-
tion, a conﬂuent monolayer was wounded by forming a scratch through the monolayer
and stained after 30 min for VE-Cadherin and ADAM9. The white arrows indicate areas
where both ADAM9 and VE-Cadherin staining is lost at the wound edge in regions
were no adjacent cell is present. Images in the right hand column are the merged
images showing overlap in staining between VE-Cadherin and ADAM9 in yellow. Scale
bars are 45 mm. B. 293T cells were transfected separately with either ADAM9-HA (red)
or ADAM9-EGFP (green) before trypsinisation, mixing and culturing as a conﬂuent
monolayer as described in the materials and methods section. Cells stained with anti-
HA (red). Solid arrows indicate localisation of ADAM9 at cell-cell contacts between
adjacent cells expressing ADAM9-HA and ADAM-EGFP. Open arrows highlight the lack
of ADAM9 staining at cell-cell junctions where one adjacent cell is not transfected.
Scale bar is 45 mm. (For interpretation of the references to colour in this ﬁgure legend,
the reader is referred to the web version of this article.)
Fig. 3. ADAM9 can self-associate through ectodomain interactions. A. Puriﬁed soluble
ADAM9 recombinant ectodomain (residues 1e698) with a c-terminal IgG Fc (ECTO-Fc)
or myc-[His]6 (ECTO-myc) tags were run on reducing SDS-PAGE and stained with
coomassie blue (left) or detected using Western blot and ECL with an anti-mouse
ADAM9 antibody (right). B. Diagrams showing the tagged ectodomain used to coat
the microtitre plate surface, the tagged ectodomain added in solution and the corre-
sponding detection antibodies used, paired with the results obtained. The negative
control in each case was the absorbance obtained in the absence of the ADAM9
ectodomain in the soluble phase and the positive control was detection of the ADAM9
ectodomain in the solid phase with the appropriate tag directed antibody. Data shown
is absorbance (A450 nm, arbitrary units). Error bars are ±SEM. * ¼ P < 0.05.
** ¼ P < 0.01.
W.R. English et al. / Biochemical and Biophysical Research Communications xxx (2017) 1e64pathologies such as cancer. ADAM9 has been shown to be involved
in the ectodomain shedding of endothelial-expressed proteins
including Tie-2, Flk-1, VCAM-1, VE-Cadherin and ACE [14,19]. In this
study we have characterised the localisation of ADAM9 in endo-
thelial cells and found it to be localised to cell-cell junctions in
conﬂuent monolayers and this overlaps with localisation of VE-
cadherin, ZO-1 and g-catenin. This localisation is dependent on
cell-cell contact as ADAM9 is primarily intracellular in subconﬂuent
cells or in cells at the edge of a scratch wound in endothelial
monolayers. This localisation is similar to the localisation of
ADAM15 in endothelial cells described by Ham et al. [6]. We have
also been able to show the ADAM9 ectodomain can self associatePlease cite this article in press as: W.R. English, et al., ADAM9 is present at
transmigration, Biochemical and Biophysical Research Communications (using recombinant proteins in vitro and that both adjacent cells
must express ADAM9 for it to localise to cell-cell junctions. It is not
known if this property is shared by ADAM15. ADAM9 has been
shown to mediate the interaction between other cells types
including monocytes, melanoma cells and ﬁbroblasts [20], indi-
cating this may be a common function for ADAM9. Both ADAM10
and 15 can regulate endothelial permeability via proteolytic and
non-proteolytic mechanisms respectively [9,17,21]. Although
ADAM9 can self-associate via its ectodomain in vitro, and this ap-
pears to occur in conﬂuent endothelial monolayers, the addition of
the recombinant ADAM9 ectodomain to conﬂuent monolayersendothelial cell - cell junctions and regulates monocytee endothelial
2017), https://doi.org/10.1016/j.bbrc.2017.09.089
Fig. 4. The soluble ADAM9 ectodomain regulates endothelial monolayer function. A. HUVEC were cultured to conﬂuence on ﬁbronectin coated transwells before incubation with 3 mM
ADAM9 ectodomain for 2 h before the addition of FITC-Dextran to measure permeability. HUVEC were also untreated (Control) or treated with 300 mM H2O2 for 30 min (H2O2) as a
positive control for induction of permeability. Fluorescence measurements (arbitrary units) are from 3 independent experiments. Error bars are ±SEM. * ¼ P < 0.05. ** ¼ P < 0.01. B.
HUVEC were cultured to conﬂuence on ﬁbronectin coated transwells before incubation with CMFDK green tracker dye labelled THP-1 cells and 3 mM ADAM9 ectodomain for 4 h.
THP-1 cells that had migrated into the lower chamber were counted indirectly via measurement of CMFDK ﬂuorescence. Data is the mean of three independent experiments. C.
Conﬂuent HUVEC in 96 well tissue culture microtire plates coated with ﬁbronectin were incubated with THP-1 CMFDK green tracker dye labelled THP-1 cells and 3 mM ADAM9
ectodomain for 30 min before ﬁxing and measurement of adherent cell number. Data is the mean of three independent experiments. Fluorescence measurements (arbitrary units)
are from 3 independent experiments. Error bars are ±SEM. * ¼ P < 0.05. ** ¼ P < 0.01.
W.R. English et al. / Biochemical and Biophysical Research Communications xxx (2017) 1e6 5could not increase endothelial monolayer permeability as has been
demonstrated for the soluble ectodomain of VE-Cadherin. Physio-
logically, ADAM9 can occur as a soluble ectodomain in addition to
the type-I transmembrane form [11]. ADAM9 increases 10 fold in
polymorphonuclear neutrophils and is produced as a soluble form
[12]. This indicates our studies with the ADAM9 ectodomain have a
physiological basis. Interestingly, although the ADAM9 ectodomain
has been shown to inhibit integrin mediated cell adhesion, it is
unable to inhibit monocyte-endothelial adhesion as strongly as
transmigration. This is similar to observations by Micocci et al. that
showed ADAM9 played a role in MDA-MB-231 endothelial trans-
migration, but not adhesion [22]. ADAM9 has been shown to
interact with a number of integrins, including those containing the
b1 subunit [23,24]. The a6b1 integrin has been shown to be
required for neutrophil transmigration, particularly in the later
stages of paracellular transmigration [25] and the ADAM9 dis-
integrin domain can also regulate neutrophil migration and
chemotaxis via a9b1 [26]. Monocytes and THP-1 cells also express
a6b1 [27,28]. The disintegrin domain of ADAM9 is able to interact
with a6 and a9, but not a5 or a4 integrins [23,24], suggesting
ADAM9may control a6b1 and/or a9b1 dependent processes during
adhesion and transendothelial migration, rather than those
dependent on a5b1 or VLA/a4b1 that are known to associate with
ADAM17 and 28 [7,10].
In conclusion we have identiﬁed ADAM9 as a component of cell
e cell junctions in endothelial cells and have demonstrated that it
can self-associate through ecotodomain interactions. Furthermore,
although the soluble ADAM9 ectodomain occurs physiologically, it
regulates endothelial e monocyte interactions rather than endo-
thelial permeability. These novel ﬁndings point to ADAM9 playing
an important role in endothelial cell biology that is distinct from
the other ADAMs.Funding
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